Key Dates

Related Announcements

• April 19, 2023 - Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional). See NOFO RFA-DA-24-038.
• March 28, 2022 - Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional). See NOFO RFA-DA-23-021.

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this  Notice is to inform potential applicants of change in the award budget language in the following Notice of Funding Opportunity (NOFO) announcements:

• RFA-DA-23-021 "Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)"

• RFA-DA-24-038 "Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)

Part 2. Full Text of Announcement

Section II. Award Information

Award Budget

Currently reads:

Total funding support (direct costs, indirect costs, fee) may not exceed $320,000 for Phase I awards and $2,500,000 for Phase II awards.

For future receipt dates of this RFA, please follow the NIDA budget limits for topics that fall under SBA-budget waiver as stated in the Omnibus Solicitation in effect at the time of your submission (see https://seed.nih.gov/small-business-funding/find-funding/sbir-sttr-funding-opportunities).

Revised to read (changes noted in bold italics):

Total funding support (direct costs, indirect costs, fee) may not exceed $400,000 for Phase I awards and $3,000,000 for Phase II awards.

All other aspects of this NOFO remain the same.

Inquiries

Please direct all inquiries to:

Leonardo Angelone, PhD
National Institute on Drug Abuse (NIDA)
Phone: 301-827-5946
Email: [email protected]